Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Influenza Diagnostic Tests Evaluated

By LabMedica International staff writers
Posted on 26 Dec 2012
Accurate diagnosis of influenza is critical for clinical management, infection control, and public health actions to minimize the burden of the disease. More...


Rapid influenza diagnostic tests (RIDTs) that detect the influenza virus nucleoprotein (NP) antigen are widely used in clinical practice for diagnosing influenza because they are simple to use and provide results within 15 minutes.

A collaboration between the US Centers of Disease Control (CDC; Atlanta, GA, USA), and the Medical College of Wisconsin (MCW; Milwaukee, WI, USA) evaluated RIDTs commercially available during the 2011–2012 influenza season. The CDC provided 16 influenza A and seven influenza B viruses to MCW. The concentration of influenza virus NP antigen was measured as μg/mL using isotope dilution tandem mass spectrometry. Swab samples or mock nasal wash specimens were prepared from several dilutions of each virus in saline.

The numbers of RIDTs that were positive, defined as at least two positive results of the three tests performed, at each dilution for each of the 23 influenza viruses were compared. The RIDTs overall had fewer positive results with viruses that had the lowest stock NP concentrations of less than 2 µg/mL. One RIDT, the SAS FluAlert Influenza A (SA Scientific; San Antonio, TX, USA) did not uniformly detect influenza A (H1N1)pdm09 (pH1N1) viruses or other influenza A viruses at high concentrations. Four RIDTs detected the majority of influenza B viruses in the third dilution samples, whereas only one RIDT, the BD Directigen EZ Flu A+B (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) detected at least 50% of all influenza A viruses in the third dilution samples.

Clinicians should be aware of the variability of RIDTs when interpreting negative results and should collect test samples using methods that can maximize the concentration of virus antigen in the sample, such as collecting adequate specimens using appropriate methods in the first 24 to 72 hours after illness onset. The study was published on November 2, 2012, in the Morbidity & Mortality Weekly Report.

Related Links:

US Centers of Disease Control
Medical College of Wisconsin
Becton, Dickinson and Company



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.